A&G Pharmaceutical

Industry / private company


Location: Columbia, MD, United States (USA) (US) US

ISNI: 0000000485016684

ROR: https://ror.org/03fa0tr49

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients (2022) Fichte A, Neumann AD, Weigelt K, Guzman J, Jansen T, Keinert J, Serrero G, et al. Journal article Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients (2021) Eckstein M, Lieb V, Jung R, Sikic D, Weigelt K, Stöhr R, Geppert CI, et al. Journal article Gp88/pgrn serum levels are associated with prognosis for oral squamous cell carcinoma patients (2021) Greither T, Steiner T, Bache M, Serrero G, Otto S, Taubert H, Eckert AW, Kappler M Journal article Expression of AR-V7 (Androgen receptor variant 7) protein in granular cytoplasmic structures is an independent prognostic factor in prostate cancer patients (2020) König P, Eckstein M, Jung R, Abdulrahman A, Guzman J, Weigelt K, Serrero G, et al. Journal article Progranulin (GP88) is an independent prognostic factor for prostate cancer patients (2020) Taubert H, Abdulrahman A, Eckstein M, Jung R, Guzman J, Weigelt K, Serrero G, et al. Conference contribution Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients (2019) Abdulrahman A, Eckstein M, Jung R, Guzman J, Weigelt K, Serrero G, Yue B, et al. Journal article Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival (2018) Greither T, Fischer K, Theil G, Marcou M, Holzhausen HJ, Weigelt K, Serrero G, et al. Journal article